| Denise Anna-marie Davies, CNM | |
|
584 Hospital Dr Ne Unit B, Bolivia, NC 28422-0020 | |
| (910) 721-4050 | |
| (910) 721-4051 |
| Full Name | Denise Anna-marie Davies |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 584 Hospital Dr Ne Unit B, Bolivia, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629204870 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 199346 (North Carolina) | Primary |
| Entity Name | Cumberland County Hospital System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881946242 PECOS PAC ID: 1850204041 Enrollment ID: O20031112000693 |
News Archive
Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.
According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston's Brigham and Women's Hospital (BWH) have found that the body's biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.
› Verified 9 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366409492 PECOS PAC ID: 1153234893 Enrollment ID: O20031121000692 |
News Archive
Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.
According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston's Brigham and Women's Hospital (BWH) have found that the body's biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.
› Verified 9 days ago
| Entity Name | Carolinas Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437607686 PECOS PAC ID: 3375449655 Enrollment ID: O20040115000819 |
News Archive
Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.
According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston's Brigham and Women's Hospital (BWH) have found that the body's biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.
› Verified 9 days ago
| Entity Name | Eastover University Obstetrics & Gynecology Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649282930 PECOS PAC ID: 5193612752 Enrollment ID: O20040301000222 |
News Archive
Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.
According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston's Brigham and Women's Hospital (BWH) have found that the body's biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.
› Verified 9 days ago
| Entity Name | Eastover Obstetrics And Gynecology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518982768 PECOS PAC ID: 2769444207 Enrollment ID: O20041115000416 |
News Archive
Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.
According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston's Brigham and Women's Hospital (BWH) have found that the body's biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.
› Verified 9 days ago
| Entity Name | Charlotte Obstetric And Gynecological Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659396893 PECOS PAC ID: 7517923964 Enrollment ID: O20041207000811 |
News Archive
Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.
According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston's Brigham and Women's Hospital (BWH) have found that the body's biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.
› Verified 9 days ago
| Entity Name | Bladen Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558537282 PECOS PAC ID: 6800967969 Enrollment ID: O20080617000314 |
News Archive
Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.
According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston's Brigham and Women's Hospital (BWH) have found that the body's biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.
› Verified 9 days ago
| Entity Name | Atrium Health North Market Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871112920 PECOS PAC ID: 1557743440 Enrollment ID: O20220809003741 |
News Archive
Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.
According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston's Brigham and Women's Hospital (BWH) have found that the body's biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Denise Anna-marie Davies, CNM Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Denise Anna-marie Davies, CNM 584 Hospital Dr Ne Unit B, Bolivia, NC 28422-0020 Ph: (910) 721-4050 |
News Archive
Millar Instruments, Inc., a medical device manufacturing firm and developer of pressure sensing technology, has released the TRM53P implantable transmitter through the partnership with Telemetry Research, Ltd. The TRM53P is the world's first, fully implantable transmitter that combines Millar's gold standard solid-state pressure sensors with Telemetry Research's next generation telemetry technology.
According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston's Brigham and Women's Hospital (BWH) have found that the body's biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.
› Verified 9 days ago
Dr. Emily Grace Lineberger, CNM, WHNP Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 584 Hospital Dr, Suite B, Bolivia, NC 28422 Phone: 630-740-6161 | |
Sarah Beth Koenigseker, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 584 Hospital Dr Ne Unit B, Bolivia, NC 28422 Phone: 910-721-4050 Fax: 910-721-4051 | |
Kiya Nichole Fox, Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 584 Hospital Dr Ne Unit B, Bolivia, NC 28422 Phone: 910-721-4050 Fax: 910-721-4051 |